Efficacy and safety of aceclofenac in the treatment of osteoarthritis: A randomized double-blind comparative clinical trial versus diclofenac - An Indian experience

Current Medical Research and Opinion

Volumn 22, Issue 5, 2006, Pages 977-988

  Pareek, Anil ^a   Chandanwale, A S ^b   Oak, J ^c   Jain, U K ^d   Kapoor, S ^e  

^a Ipca Laboratories Ltd   (India)

^b SIR J J GROUP OF HOSPITALS   (India)

^c LOKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND GENERAL HOSPITAL   (India)

^d KING GEORGE'S MEDICAL UNIVERSITY   (India)

^e MAULANA AZAD MEDICAL COLLEGE   (India)

Author keywords

Aceclofenac; Non steroidal anti inflammatory drugs; Osteoarthritis

Indexed keywords

ACECLOFENAC; DICLOFENAC;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EPIGASTRIC DISCOMFORT; FEMALE; FLATULENCE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; OSTEOARTHRITIS; TREATMENT OUTCOME;

EID: 33745054917     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104722     Document Type: Article

References (26)

1. Walker-Bone K, Javaid K, Arden N, et al. Regular review: medical management of osteoarthritis. BMJ 2000;321: 936-40
2. Sack KE. Osteoarthritis. A continuing challenge. West J Med 1995;163:579-86
3. Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 2005;35:1-10
4. Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004;329:1317
5. Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27
6. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83
7. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43:370-7
8. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004;364:2021-9
9. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91
10. Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61:1351-78
11. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother 2004;5:1347-57
12. Gonzalez E, de la Cruz C, de Nicolas R, et al. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 1994;41:171-8
13. Yamazaki R, Kawai S, Matsuzaki T, et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 1997;329:181-7
14. Yamazaki R, Kawai S, Matsumoto T, et al. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J Pharmacol Exp Ther 1999;289:676-81
15. Hinz B, Brune K. Pain and osteoarthritis: new drugs and mechanisms. Curr Opin Rheumatol 2004;16:628-33
16. Diaz C, Rodriguez de la Serna A, Geli C, et al. Efficacy and tolerability of aceclofenac versus diclofenac in the treatment of knee osteoarthritis: a multicentre study. Eur J Rheumatol Inflamm 1996;16:17-22
17. Kornasoff D, Frerick H, Bowdler J, et al. Aceclofenac is a well tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheumatol 1997;16:32-8
18. Perez Busquier M, Calero E, Rodriguez M, et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheumatol 1997;16:154-9
19. Preservex tablets. In: Walker G (Ed). ABPI compendium of data sheets and summaries of product characteristics 1999-2000. London: Datapharm Publications Ltd, 1999:1680-1
20. Torri G, Vignati C, Agrifoglio E, et al. Aceclofenac versus piroxicam in the management of osteoarthritis of the knee: a double-blind controlled study. Curr Ther Res 1994;55:576-83
21. Ward DE, Veys EM, Bowdler JM, et al. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995;14:656-62
22. Maneiro E, Lopez-Armada MJ, Fernandez-Sueiro JL, et al. Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J Rheumatol 2001;28:2692-9
23. Akimoto H, Yamazaki R, Hashimoto S, et al. 4′-Hydroxyaceclofenac suppresses the interleukin-1 induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol 2000;401:429-36
24. Yamazaki R, Kawai S, Mizushima Y, et al. A major metabolite of aceclofenac, 4′-hydroxyaceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and prostromelysin-1/proMMP-3 by human rheumatoid synovial cells. Inflamm Res 2000;49:133-8
25. Spiegel BM, Targownik L, Dulai GS, et al. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003;138:795-806
26. Haq I, Murphy E, Dacre J. Osteoarthritis. Postgrad Med J 2003;79(933):377-83